| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Rabusertib (also known as IC-83; LY-2603618; LY 2603618; IC83) is a novel, potent and selective Chk1 (cell cycle checkpoint kinase 2) inhibitor with potential antitumor activity. In a cell-free assay, it inhibits Chk1 with an IC50 of 7 nM and may have anti-tumor effects. By binding to and inhibiting the activity of chk2, LY2603618 may increase the antitumor efficacies of different chemotherapeutic agents by preventing DNA damage caused by DNA-damaging agents from being repaired. Double-strand breaks (DSBs) activate ATP-dependent serine-threonine kinase Chk2, which is an essential part of the DNA replication-monitoring checkpoint system and is overexpressed by a range of cancer cell types.
| Targets |
Chk1 (IC50 = 7 nM); Chk2 (IC50 = 12000 nM); PDK1 (IC50 = 893 nM); CAMK2 (IC50 = 1550 nM); VEGFR3 (IC50 = 2128 nM); MET (IC50 = 2200 nM); JNK1 (IC50 = 4930 nM); RSK2 (IC50 = 5700 nM); NTRK1 (IC50 = 12000 nM)
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Cell Assay |
Cells are plated on 96-well tissue culture plates at a density of 2.5×103 per well, and then incubated for one cell doubling (18–24 hours). The final concentration range of 1-1000 nM is covered by half-log steps when setting up gemcitabine dilutions. Rabusertib (LY2603618) is made by dilutions in DMSO to a final concentration of 5000×, and then a 1000-fold dilution in medium to produce 5× stocks that are added to wells. Rabusertib (LY2603618) is added about 24 hours after the addition of gemcitabine. Three copies of each combination are made. Following the addition of Rabusertib (LY2603618) and allowing two cell doublings, MTS/PMS reagent is added to each well in accordance with the manufacturer's instructions. A Spectra Max 250 spectrophotometer is used to measure absorbance at 490 nm, and GraphPad Prism 4.0 is used to analyze the results. Non-linear regression is used to fit dose-response curves, with the bottom fits being limited to 0% inhibition[1].
|
|
| Animal Protocol |
|
|
| References |
|
|
| Additional Infomation |
1-[5-bromo-4-methyl-2-[[(2S)-2-morpholinyl]methoxy]phenyl]-3-(5-methyl-2-pyrazinyl)urea is a member of ureas.
Rabusertib has been used in trials studying the treatment of Cancer, Solid Tumors, Advanced Cancer, Pancreatic Neoplasms, and Non Small Cell Lung Cancer. Rabusertib is an inhibitor of the cell cycle checkpoint kinase 2 (chk2) with potential chemopotentiating activity. Rabusertib binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents, thus potentiating the antitumor efficacies of various chemotherapeutic agents. Chk2, an ATP-dependent serine-threonine kinase, is a key component in the DNA replication-monitoring checkpoint system and is activated by double-stranded breaks (DSBs); activated chk2 is overexpressed by a variety of cancer cell types. |
| Molecular Formula |
C18H22BRN5O3
|
|
|---|---|---|
| Molecular Weight |
436.3
|
|
| Exact Mass |
435.09
|
|
| Elemental Analysis |
C, 49.55; H, 5.08; Br, 18.31; N, 16.05; O, 11.00
|
|
| CAS # |
911222-45-2
|
|
| Related CAS # |
|
|
| PubChem CID |
11955855
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.5±0.1 g/cm3
|
|
| Boiling Point |
503.1±50.0 °C at 760 mmHg
|
|
| Flash Point |
258.1±30.1 °C
|
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
|
| Index of Refraction |
1.633
|
|
| LogP |
2.1
|
|
| Hydrogen Bond Donor Count |
3
|
|
| Hydrogen Bond Acceptor Count |
6
|
|
| Rotatable Bond Count |
5
|
|
| Heavy Atom Count |
27
|
|
| Complexity |
486
|
|
| Defined Atom Stereocenter Count |
1
|
|
| SMILES |
O(C1=CC(C)=C(Br)C=C1NC(=O)NC1N=CC(C)=NC=1)C[C@H]1OCCNC1
|
|
| InChi Key |
SYYBDNPGDKKJDU-ZDUSSCGKSA-N
|
|
| InChi Code |
InChI=1S/C18H22BrN5O3/c1-11-5-16(27-10-13-8-20-3-4-26-13)15(6-14(11)19)23-18(25)24-17-9-21-12(2)7-22-17/h5-7,9,13,20H,3-4,8,10H2,1-2H3,(H2,22,23,24,25)/t13-/m0/s1
|
|
| Chemical Name |
1-[5-bromo-4-methyl-2-[[(2S)-morpholin-2-yl]methoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.73 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 2% DMSO +30% PEG400+0.5% Tween80+5% Propylene glycol : 30mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2920 mL | 11.4600 mL | 22.9200 mL | |
| 5 mM | 0.4584 mL | 2.2920 mL | 4.5840 mL | |
| 10 mM | 0.2292 mL | 1.1460 mL | 2.2920 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
